Results 11 to 20 of about 9,220 (202)

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted Atovaquone

Advanced Science, 2022
Atovaquone, an FDA‐approved drug for malaria, is known to inhibit mitochondrial electron transport. A recently synthesized mitochondria‐targeted atovaquone increased mitochondrial accumulation and antitumor activity in vitro. Using an in situ vaccination
Mofei Huang, Donghai Xiong, Jing Pan
exaly   +3 more sources

Atovaquone-induced oxidative stress activates the pentose phosphate pathway and Immunogenic cell death in ovarian cancer [PDF]

Scientific Reports
Atovaquone, an FDA-approved oxidative phosphorylation (OXPHOS) inhibitor, has shown promise in the treatment of epithelial ovarian cancer (EOC), the deadliest gynecologic malignancy.
Mayra Betancourt Ponce, Nicha Boonpattrawong, Alexander J. Fagan, Michael Newton, Manish Patankar, Lisa Barroilhet   +5 more
doaj   +3 more sources

Atovaquone-induced activation of the PERK/eIF2α signaling axis mitigates metabolic radiosensitisation [PDF]

Cell Communication and Signaling
Background Hypoxia, a key feature of most solid tumours, including head and neck cancer, reduces radiotherapy efficacy by promoting radiation resistance through micro-environmental and genomic alterations.
Jie Feng, Varun Pathak, Niall M. Byrne, Sarah Chambers, Tongchuan Wang, Rayhanul Islam, Reinhold J. Medina, Jonathan A. Coulter   +7 more
doaj   +3 more sources

Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway

BMC Cancer, 2023
Background Colorectal cancer is a common malignant tumour. Invasive growth and distant metastasis are the main characteristics of its malignant biological behaviour, and they are also the primary factors leading to death in colon cancer patients ...
Bin Liu, Xin Zheng, Jiajun Li, Peng Yao, Peng Guo, Wei Liu, Gaoping Zhao   +6 more
doaj   +2 more sources

Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

Frontiers in Pharmacology, 2022
Background: An in silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (Mpro), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice.
Mamta K. Jain, Mamta K. Jain, James A. De Lemos, James A. De Lemos, Darren K. McGuire, Darren K. McGuire, Colby. Ayers, Jennifer L. Eitson, Claudia L. Sanchez, Dena Kamel, Jessica A. Meisner, Emilia V. Thomas, Anita A. Hegde, Anita A. Hegde, Satish Mocherla, Satish Mocherla, Joslyn K. Strebe, Xilong Li, Noelle S. Williams, Chao Xing, Mahmoud S. Ahmed, Ping Wang, Hesham A. Sadek, Hesham A. Sadek, John W. Schoggins   +24 more
doaj   +2 more sources

Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito

Nature Communications, 2023
Long-acting injectable medications, such as atovaquone, offer the prospect of a “chemical vaccine” for malaria, combining drug efficacy with vaccine durability. However, selection and transmission of drug-resistant parasites is of concern.
Victoria A. Balta, Deborah Stiffler, Abeer Sayeed, Abhai K. Tripathi, Rubayet Elahi, Godfree Mlambo, Rahul P. Bakshi, Amanda G. Dziedzic, Anne E. Jedlicka, Elizabeth Nenortas, Keyla Romero-Rodriguez, Matthew A. Canonizado, Alexis Mann, Andrew Owen, David J. Sullivan, Sean T. Prigge, Photini Sinnis, Theresa A. Shapiro   +17 more
doaj   +2 more sources

Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis

Pharmaceuticals, 2021
Triple-negative breast cancer (TNBC) is considered to be the most aggressive and malignant neoplasm and is highly metastatic in nature. In the current study, we investigated the anti-metastatic potential of atovaquone, a protozoal drug prescribed for ...
Nehal Gupta, Sanjay K. Srivastava
doaj   +2 more sources

Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study

BMC Medicine, 2022
Background Individuals with a family history of colorectal cancer (CRC) are at a high risk of developing CRC. Preclinical studies suggest that the anti-malaria drug proguanil and atovaquone might play a role in preventing CRC, but population-based ...
Naiqi Zhang, Jan Sundquist, Kristina Sundquist, Jianguang Ji   +3 more
doaj   +2 more sources

Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients

EJNMMI Research, 2021
Background Tumour hypoxia promotes an aggressive tumour phenotype and enhances resistance to anticancer treatments. Following the recent observation that the mitochondrial inhibitor atovaquone increases tumour oxygenation in NSCLC, we sought to assess ...
Pauline Bourigault, Michael Skwarski, Ruth E. Macpherson, Geoff S. Higgins, Daniel R. McGowan   +4 more
doaj   +2 more sources

Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models

Cell Death and Disease
Immune checkpoint blockade (ICB) provides effective and durable responses for several tumour types by unleashing an immune response directed against cancer cells.
Gonzalo Rodriguez-Berriguete, Rathi Puliyadi, Nicole Machado, Alessandro Barberis, Remko Prevo, Martin McLaughlin, Francesca M. Buffa, Kevin J. Harrington, Geoff S. Higgins   +8 more
doaj   +2 more sources